Skip to main content
Premium Trial:

Request an Annual Quote

Novartis Spends $1.2M to Buy Additional Alnylam Shares as Part of Companies' 2005 Alliance


Alnylam Pharmaceuticals has pocketed around $1.2 million after Novartis fully exercised its right to purchase an additional 65,922 unregistered shares of Alnylam's common stock, pursuant to the companies' 2005 drug-discovery and -development deal, Novartis said this week.

Novartis, which Alnylam lists as its second biggest shareholder, said its decision to purchase the additional stock, for which it paid $17.50 per share, allows it to maintain its current 13.4 percent stake in Alnylam.

In September 2005, the companies first announced that they had forged a three-year alliance to develop drugs based on Alnylam's RNAi technology (see RNAi News, 9/9/2005). As part of that arrangement, Novartis took what was then a 19.9 percent stake in Alnylam.

Last summer, Alnylam announced that the arrangement had been extended for an additional year and will run through October 2009 (see RNAi News, 7/17/2008).

Shares in Alnylam closed down 1.34 percent at $18.37 on Wednesday.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.